Alkermes Plc - ALKS - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Alkermes Plc - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
ALKS	Nasdaq	8731	http://a.alkermes.com/	29.91 0.00
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Alkermes Plc The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter) - Jun 18th, 2013 1:20 pm Following The Data Leads Alkermes In Right Direction - Jun 14th, 2013 2:49 pm Alkermes' CEO Presents at Goldman Sachs Healthcare Conference (Transcript) - Jun 13th, 2013 2:42 pm Alkermes Changing The Standard Of Care For Schizophrenia - Jun 13th, 2013 2:06 pm 2 Healthcare Companies With Recent Intensive Insider Selling - Jun 13th, 2013 7:37 am When It Comes To Biotech, Diversity Is Key - Jun 12th, 2013 5:51 am Top-Quality Foreign Stocks Re-Entering Buy Zones - Jun 10th, 2013 4:46 pm A Full Pipeline At Alkermes - Jun 10th, 2013 5:00 am Celgene, Biogen Lead IBD 50's Top 5 Biotechs - Jun 5th, 2013 2:33 pm Biogen Delays EU Launch of Tecfidera - May 31st, 2013 8:50 am Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting - May 31st, 2013 5:00 am Encouraging Data from Alkermes - May 29th, 2013 2:40 pm Amgen-Astellas Collaborate - May 29th, 2013 2:16 pm Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences - May 29th, 2013 2:00 pm Alkermes' Management Presents at Deutsche Bank 38th Annual dbAccess Health Care Conference (Transcript) - May 29th, 2013 12:36 pm ALKERMES PLC. Financials - May 29th, 2013 11:04 am A Fundamental Take On Alkermes' Turnaround Story - May 29th, 2013 10:19 am Analysts' Actions: ALKS CBI CMA SEAS - May 29th, 2013 6:23 am Alkermes Presents Positive Results from Phase 1 Study of ALKS 3831 as a Broad Spectrum Treatment for Schizophrenia - May 28th, 2013 5:00 am Alkermes PLC Earnings Call Insights: Abilify Maintena Launch and 9070 Clinical Trials - May 26th, 2013 10:01 am View All Current Headlines >>